<div id="content" class="col-md-12" style="">
<div data-drupal-messages-fallback="" class="hidden"/><div id="block-medsites-page-title" class="widget block">
<h1><span property="schema:name">Hypercoagulable States</span>
</h1>
</div>
<div id="block-medsites-content" class="widget block">
<article data-history-node-id="1026" role="article" about="/commodorecompendium/hypercoagulable-states" typeof="schema:WebPage">
<div>
<div property="schema:text" class="field field--name-body field--type-text-with-summary field--label-hidden field__item"><div class="WordSection1">
<div style="border-bottom:solid windowtext 1.0pt; border-top:double windowtext 1.5pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
<p style="border:none; padding:0in"><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="font-family:Palatino">Hypercoagulable States – Chris Cann</span></span></b></span></span></span></span></p>
</div>
<p><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Background</span></span></span></span></span></span></p>
<ul>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Virchow’s triad: 1. Hypercoagulability 2. Blood flow stasis 3. Endothelial injury </span></span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Diagnostic thrombophilia testing indications: </span></span></span></span></span></span></span>
<ul style="list-style-type:circle">
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Idiopathic or recurrent VTE</span></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">First VTE at &lt;40 years old</span></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">VTE in the setting of strong family history </span></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">VTE in unusual vascular site (cerebral, renal, mesenteric)</span></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Recurrent pregnancy loss</span></span></span></span></span></span></span></span></li>
</ul>
</li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Separated into Acquired and Hereditary factors:</span></span></span></span></span></span></span>
<ul style="list-style-type:circle">
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Hereditary: Factor V Leiden, Prothrombin mutation, Protein C/S deficiency, Antithrombin deficiency</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection1"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Acquired</span></span></span><span style="font-size:12.0pt"><span style="font-family:Palatino">: </span></span></span></span></span></span></span>
<ul>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">APLS</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">HIT</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Major surgery/trauma</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Nephrotic Syndrome</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Smoking</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Pregnancy</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Oral Contraceptives</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Immobilization (bedridden, hip/knee replacement) Infection in past 3 months</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Active malignancy</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection2"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Estrogen replacement therapy</span></span></span></span></span></span></span></li>
</ul>
</li>
</ul>
</li>
</ul>
</div>
<div class="WordSection3">
<ul>
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Testing: all specific testing for hereditary disorders and APS should be performed at least 4-6 weeks after an acute thrombotic event or discontinuation of anticoagulant/thrombolytic therapies to avoid interference</span></span></span></span></span></span></span></li>
</ul>
<p> </p>
<p> </p>
<div style="border-bottom:solid windowtext 1.0pt; border-top:solid windowtext 1.0pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
<p style="border:none; padding:0in"><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family:Palatino">Antiphospholipid antibody syndrome (APLS):</span></span></span></b></span></span></span></span></p>
</div>
<p><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Background</span></span></span></span></span></span></p>
<ul>
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Most<span style="color:black"> common acquired factor (anti-phospholipid antibodies present in 3-5% population)</span></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Recurrent<span style="color:black"> pregnancy loss, provoked DVT in young, unprovoked VTE and arterial thrombosis in young, thrombosis unusual sites, thrombosis in autoimmune disease</span></span></span></span></span></span></span></span></li>
</ul>
<p style="margin-left:24px"> </p>
<p><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Evaluation</span></span></span></span></span></span></span></p>
<ul>
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Positive for at least 1 lab criterion on at least 2 occasions, at least 12 weeks apart:</span></span></span></span></span></span></span>
<ul style="list-style-type:circle">
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Lupus</span></span></span><span style="font-size:12.0pt"><span style="font-family:Palatino"> anticoagulant: can occur in relation to drugs or infection; transient are associated with thrombotic risk</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Anticardiolipin</span></span></span><span style="font-size:12.0pt"><span style="font-family:Palatino"> antibodies</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">B2GP1</span></span></span><span style="font-size:12.0pt"><span style="font-family:Palatino"> (anti-beta2-glycoprotein) antibodies </span></span></span></span></span></span></span></li>
</ul>
</li>
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Must also meet at least 1 of the following clinical criteria:</span></span></span></span></span></span></span>
<ul style="list-style-type:circle">
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Vascular</span></span></span><span style="font-size:12.0pt"><span style="font-family:Palatino"> thrombosis: DVT, arterial thrombosis, or small vessel thrombosis of any organ</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Pregnancy</span></span></span><span style="font-size:12.0pt"><span style="font-family:Palatino"> loss: there are specific criteria for this – consult UpToDate or other resource</span></span></span></span></span></span></span></li>
</ul>
</li>
</ul>
<p style="margin-left:37px"> </p>
<p><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Management</span></span></span></span></span></span></span></span></p>
<ul>
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Aspirin for primary prevention; warfarin for treatment (INR 2-3)</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Do NOT use DOACs for APLS (see TRAPS trial: rivaroxaban inferior to warfarin)</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection3"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Rituximab for recurrent thrombosis despite anticoagulation (controversial)</span></span></span></span></span></span></span></li>
</ul>
</div>
<p> </p>
<div class="WordSection4"> </div>
<p> </p>
<div class="WordSection5">
<div style="border-bottom:solid windowtext 1.0pt; border-top:solid windowtext 1.0pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
<p style="border:none; padding:0in"><span style="page:WordSection5"><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family:Palatino">Heparin-induced thrombocytopenia (HIT)</span></span></span></b></span></span></span></span></p>
</div>
<p><span style="page:WordSection5"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Type</span></span></span><span style="font-size:12.0pt"><span style="font-family:Palatino"> 1: Mild and self-limited (not immune-mediated)</span></span></span></span></span></span></span></p>
<ul>
<li><span style="page:WordSection5"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Occurs within the first 2 days of first-time exposure</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection5"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Platelet count normalizes with continued heparin therapy</span></span></span></span></span></span></span></li>
</ul>
<p style="margin-left:37px"> </p>
<p><span style="page:WordSection5"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Type 2 (what we typically refer to as HIT): Immune mediated</span></span></span></span></span></span></span></p>
<ul>
<li><span style="page:WordSection5"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Fall in plt 30% to over 50% (even if plt count &gt;150) and/or thrombotic event has occurred</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection5"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">4-10 days after new exposure to heparin derivative OR≤ </span></span></span></span></span></span></span></li>
<li><span style="page:WordSection5"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">1 day after restarting heparin derivative that had been used 30-100 days prior </span></span></span></span></span></span></span>
<ul style="list-style-type:circle">
<li><span style="page:WordSection5"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">If exposed to heparin within 100 days, will have platelet drop within 24 hr</span></span></span></span></span></span></span></li>
</ul>
</li>
<li><span style="page:WordSection5"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Frequency: unfractionated heparin &gt; LMWH;  Surgical wards &gt;  medical wards</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection5"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">50% will have thrombotic event in 30 days if HIT is untreated, with 20% mortality </span></span></span></span></span></span></span></li>
<li><span style="page:WordSection5"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Arterial thrombi are common in HIT</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection5"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">HIT results from antibodies to complexes of platelet factor 4 (PF4) and heparin, further activating platelets (the activated platelets aggregate causing thrombocytopenia)</span></span></span></span></span></span></span></li>
</ul>
<p style="margin-left:24px"> </p>
<p><span style="page:WordSection5"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Evaluation</span></span></span></span></span></span></span></span></p>
<ul>
<li><span style="page:WordSection5"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><a name="FourT" id="FourT"/><span style="font-size:12.0pt"><span style="font-family:Palatino">4T score (0-8 points): </span></span></span></span></span></span></span>
<ul style="list-style-type:circle">
<li><span style="page:WordSection5"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Thrombocytopenia (0-2 pts): degree and nadir of platelet count drop</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection5"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Timing (0-2 pts): timing of fall after initial or recurrent heparin exposure</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection5"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Thrombosis (0-2 pts): thrombosis, skin necrosis, non-necrotizing lesions, acute systemic reaction to heparin</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection5"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Other causes of thrombocytopenia (0-2 pts): more points if no alternate cause  </span></span></span></span></span></span></span></li>
</ul>
</li>
<li><span style="page:WordSection5"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Solid-phase ELISA for heparin-PF4 antibodies:</span></span></span></span></span></span></span>​​​​​​​
	<ul>
<li><span style="page:WordSection6"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">0.2-0.4 is indeterminate</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection6"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">&gt; 0.4 is positive</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection6"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">&gt; 1.4 HIT is likely</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection6"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">&gt; 2 confirms HIT</span></span></span></span></span></span></span>​​​​​​​</li>
<li><span style="page:WordSection7"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">The lab at VUMC will perform functional SRA reflexively for all values &gt;0.2</span></span></span></span></span></span></span></li>
</ul>
</li>
</ul>
</div>
<p> </p>
<div class="WordSection8">
<p><span style="page:WordSection8"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino"><span style="color:black">Management</span></span></span></span></span></span></span></span></p>
<ul>
<li><span style="page:WordSection8"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">0-3 points: Low concern for HIT; can restart heparin</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection8"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">4-5 points: Intermediate probability (~10%) - hold heparin, <b>start non-heparin anticoagulant</b></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection8"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">6 points: High probability (~50%) - hold heparin, <b>start non-heparin anticoagulant</b></span></span></span></span></span></span></span></li>
<li><span style="page:WordSection8"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Argatroban (direct thrombin inhibitor) for prophylaxis and treatment of thrombosis</span></span></span></span></span></span></span>
<ul style="list-style-type:circle">
<li><span style="page:WordSection8"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Avoid platelet transfusions as can increase thrombogenic effect</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection8"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Avoid warfarin until complete platelet recovery as may cause microthrombosis</span></span></span></span></span></span></span></li>
</ul>
</li>
<li><span style="page:WordSection8"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Hematology consult for all confirmed HIT</span></span></span></span></span></span></span></li>
</ul>
<p style="margin-left:12px"> </p>
<p style="margin-left:12px"> </p>
<div style="border-bottom:solid windowtext 1.0pt; border-top:solid windowtext 1.0pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
<p style="border:none; padding:0in"><span style="page:WordSection8"><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family:Palatino">Factor V Leiden mutation</span></span></span></b></span></span></span></span></p>
</div>
<p><span style="page:WordSection8"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:list 1.25in"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Evaluation</span></span></span></span></span></span></span></p>
<ul>
<li><span style="page:WordSection8"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Activated protein C resistance assay</span></span></span></span></span></span></span>
<ul style="list-style-type:circle">
<li><span style="page:WordSection8"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">APC ratio in patient vs normal</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection8"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">normal &gt;2.0, heterozygotes 1.5-2.0, homozygotes &lt;1.5</span></span></span></span></span></span></span></li>
</ul>
</li>
<li><span style="page:WordSection8"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">FVL mutation is then determined via PCR</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection8"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Screen with APC assay rather than PCR initially; cost effective</span></span></span></span></span></span></span></li>
</ul>
<p style="margin-left:24px"> </p>
<p><span style="page:WordSection8"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Management </span></span></span></span></span></span></span></p>
<ul>
<li><span style="page:WordSection8"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">VTE treatment same as general population</span></span></span></span></span></span></span>
<ul style="list-style-type:circle">
<li><span style="page:WordSection8"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">VTE 4-8x risk in heterozygotes; 80x risk in homozygotes</span></span></span></span></span></span></span></li>
</ul>
</li>
<li><span style="page:WordSection8"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Avoid OCPs: increased risk for VTE </span></span></span></span></span></span></span></li>
</ul>
</div>
<p> </p>
<div class="WordSection9"> </div>
<p> </p>
<div class="WordSection10">
<div style="border-bottom:solid windowtext 1.0pt; border-top:solid windowtext 1.0pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
<p style="border:none; padding:0in"><span style="page:WordSection10"><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family:Palatino">Prothrombin gene mutation</span></span></span></b></span></span></span></span></p>
</div>
<p><span style="page:WordSection10"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:list 1.25in"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Evaluation: PCR of G20210A mutation (2-4% Europeans carry mutation)</span></span></span></span></span></span></span></p>
<p style="margin-left:24px"> </p>
<p><span style="page:WordSection10"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Management: VTE treatment same as general population &amp; Avoid OCPs</span></span></span></span></span></span></span></p>
<p style="margin-left:120px"> </p>
<div style="border-bottom:solid windowtext 1.0pt; border-top:solid windowtext 1.0pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
<p style="border:none; padding:0in"><span style="page:WordSection10"><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family:Palatino">Protein C &amp; S Deficiency </span></span></span></b></span></span></span></span></p>
</div>
<p><span style="page:WordSection10"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Background </span></span></span></span></span></span></span></p>
<ul>
<li><span style="page:WordSection10"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Autosomal dominant; first event occurs between 10-50 years of age</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection10"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Synthesized in liver and Vit K dependent, therefore low levels in hepatic dysfunction and warfarin use/vitamin K deficiency</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection10"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Protein C: low in settings of thrombosis, DIC, nephrotic syndrome, intra/post-op</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection10"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Protein S : low in infectious (HIV) and autoimmune processes (IBD)</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection10"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background:white"><span style="font-family:Palatino"><span style="color:black">Protein S decreases during pregnancy (decreased free Protein S, normal total Protein S) </span></span></span></span></span></span></span></span>
<ul style="list-style-type:circle">
<li><span style="page:WordSection10"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Do not misdiagnose a pregnant patient with PS deficiency</span></span></span></span></span></span></span></li>
</ul>
</li>
</ul>
<p> </p>
<p><span style="page:WordSection10"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Evaluation</span></span></span></span></span></span></span></p>
<ul>
<li><span style="page:WordSection10"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Functional Protein C &amp; S assays</span></span></span></span></span></span></span>
<ul style="list-style-type:circle">
<li><span style="page:WordSection10"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Used for screening prior to use of immunologic methods to measure free protein levels</span></span></span></span></span></span></span></li>
</ul>
</li>
</ul>
<p> </p>
<p><span style="page:WordSection10"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Management</span></span></span></span></span></span></span></p>
<ul>
<li><span style="page:WordSection10"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">VTE treatment same as general population</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection10"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Avoid OCPs</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection10"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">High risk patients may require protein C concentrate prior to surgery</span></span></span></span></span></span></span></li>
<li><span style="page:WordSection10"><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Increased risk of warfarin-induced skin necrosis </span></span></span></span></span></span></span></li>
</ul>
</div>
<p> </p>
<p style="margin-left:24px"> </p>
<div style="border-bottom:solid windowtext 1.0pt; border-top:solid windowtext 1.0pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
<p style="border:none; padding:0in"><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family:Palatino">Antithrombin deficiency</span></span></span></b></span></span></span></p>
</div>
<p><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Background</span></span></span></span></span></p>
<ul>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Autosomal dominant, does not skip generations </span></span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">VTE in unusual sites (cerebral sinuses, renal veins)</span></span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Present &lt; 50 y/o, but rarely in first two decades</span></span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Decreased in liver disease, nephrotic syndrome, protein losing enteropathy, burn, trauma, bypass surgery, metastatic tumors, premenopausal, OCP use, pregnancy </span></span></span></span></span></span></li>
</ul>
<p> </p>
<p><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Evaluation</span></span></span></span></span></span></p>
<ul>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Functional antithrombin activity (AT-heparin cofactor assay)</span></span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Then perform antigen quantity testing</span></span></span></span></span></span></li>
</ul>
<p style="margin-left:24px"> </p>
<p><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Management</span></span></span></span></span></span></p>
<ul>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Can use Argatroban as does not require antithrombin function</span></span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="tab-stops:9.0pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Warfarin preferred in VTE (titrate up based on expression of antithrombin deficiency)</span></span></span></span></span></span></li>
</ul>
</div>
</div>
</article>
</div>
</div>